Biological Models in Radiopharmaceutical Development [electronic resource] /
Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals.
Main Authors: | , |
---|---|
Format: | Texto biblioteca |
Language: | eng |
Published: |
Dordrecht : Springer Netherlands,
1996
|
Subjects: | Medicine., Laboratory medicine., Pharmacology., Radiology., Nuclear medicine., Veterinary medicine., Medicine & Public Health., Diagnostic Radiology., Nuclear Medicine., Veterinary Medicine., Pharmacology/Toxicology., Laboratory Medicine., |
Online Access: | http://dx.doi.org/10.1007/978-94-009-0159-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
KOHA-OAI-TEST:209884 |
---|---|
record_format |
koha |
institution |
COLPOS |
collection |
Koha |
country |
México |
countrycode |
MX |
component |
Bibliográfico |
access |
En linea En linea |
databasecode |
cat-colpos |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Departamento de documentación y biblioteca de COLPOS |
language |
eng |
topic |
Medicine. Laboratory medicine. Pharmacology. Radiology. Nuclear medicine. Veterinary medicine. Medicine & Public Health. Diagnostic Radiology. Nuclear Medicine. Veterinary Medicine. Pharmacology/Toxicology. Laboratory Medicine. Medicine. Laboratory medicine. Pharmacology. Radiology. Nuclear medicine. Veterinary medicine. Medicine & Public Health. Diagnostic Radiology. Nuclear Medicine. Veterinary Medicine. Pharmacology/Toxicology. Laboratory Medicine. |
spellingShingle |
Medicine. Laboratory medicine. Pharmacology. Radiology. Nuclear medicine. Veterinary medicine. Medicine & Public Health. Diagnostic Radiology. Nuclear Medicine. Veterinary Medicine. Pharmacology/Toxicology. Laboratory Medicine. Medicine. Laboratory medicine. Pharmacology. Radiology. Nuclear medicine. Veterinary medicine. Medicine & Public Health. Diagnostic Radiology. Nuclear Medicine. Veterinary Medicine. Pharmacology/Toxicology. Laboratory Medicine. Lambrecht, Richard M. author. SpringerLink (Online service) Biological Models in Radiopharmaceutical Development [electronic resource] / |
description |
Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals. |
format |
Texto |
topic_facet |
Medicine. Laboratory medicine. Pharmacology. Radiology. Nuclear medicine. Veterinary medicine. Medicine & Public Health. Diagnostic Radiology. Nuclear Medicine. Veterinary Medicine. Pharmacology/Toxicology. Laboratory Medicine. |
author |
Lambrecht, Richard M. author. SpringerLink (Online service) |
author_facet |
Lambrecht, Richard M. author. SpringerLink (Online service) |
author_sort |
Lambrecht, Richard M. author. |
title |
Biological Models in Radiopharmaceutical Development [electronic resource] / |
title_short |
Biological Models in Radiopharmaceutical Development [electronic resource] / |
title_full |
Biological Models in Radiopharmaceutical Development [electronic resource] / |
title_fullStr |
Biological Models in Radiopharmaceutical Development [electronic resource] / |
title_full_unstemmed |
Biological Models in Radiopharmaceutical Development [electronic resource] / |
title_sort |
biological models in radiopharmaceutical development [electronic resource] / |
publisher |
Dordrecht : Springer Netherlands, |
publishDate |
1996 |
url |
http://dx.doi.org/10.1007/978-94-009-0159-9 |
work_keys_str_mv |
AT lambrechtrichardmauthor biologicalmodelsinradiopharmaceuticaldevelopmentelectronicresource AT springerlinkonlineservice biologicalmodelsinradiopharmaceuticaldevelopmentelectronicresource |
_version_ |
1756268720225779712 |
spelling |
KOHA-OAI-TEST:2098842018-07-30T23:41:57ZBiological Models in Radiopharmaceutical Development [electronic resource] / Lambrecht, Richard M. author. SpringerLink (Online service) textDordrecht : Springer Netherlands,1996.engRadiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals.Preface -- Acknowledgements -- Scope of the Work -- Guidelines for Research with Animals -- Moral and Ethical Considerations -- Principles and Training Programs -- Design of Candidate Radiopharmaceuticals -- Identification of Clinical Need -- Choice of Radionuclide -- Screening Studies -- Drug Development -- Concept of Biological Model -- In Vitro Models -- Choice of Biological Models -- Species Variations -- Transgenic Mice -- Dogs and Kangaroos -- Poison Arrow Frog -- Giraffe -- Tomographic Phisiological Chemistry -- ARG -- SPET -- PET -- SIMS -- Keyword Guide to Selection of Biological Models -- References -- Glossary of Abbreviations.Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals.Medicine.Laboratory medicine.Pharmacology.Radiology.Nuclear medicine.Veterinary medicine.Medicine & Public Health.Diagnostic Radiology.Nuclear Medicine.Veterinary Medicine.Pharmacology/Toxicology.Laboratory Medicine.Springer eBookshttp://dx.doi.org/10.1007/978-94-009-0159-9URN:ISBN:9789400901599 |